BioSpace News Archive

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate updates. We estimate that nearly 1,000 new patients were treated with VYVGART in January 2024 alone; expe

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, announced that management will be participating in three upcoming investor conferences.

Oragenics, Inc., a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer to sell shares of its common stock in lieu thereof) in an underwritten public offering.

ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) (“ME Therapeutics” or the “Company”), a preclinical stage biotechnology company working on

Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Sotera Health Company announced the launch of a secondary offering of 25,000,000 shares of its common stock, par value $0.01 per share.

MacroGenics, Inc. (Nasdaq: MGNX) today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on February 26, 2024, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.

Asep Medical Holdings Inc. is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.